Celgene Higher Off Positive Phase II Sunbeam Trial Of Oral Ozanimod

Loading...
Loading...

Celgene Corporation CELG shares are trading higher by $2.00 at $120.66 in Friday's session. The catalyst for the rally is a Phase II study of Oral Ozanimod with relapsing MS meeting its primary endpoint in reducing ARR, measured endpoints.

After a higher open, it had a brief retreat but found found support just under above Thursday's close ($118.66), only reaching $118.81 before continuing its move higher.

So far, the ensuing rally has cleared the pair of highs from Wednesday ($120.63) and Thursday ($120.77), reaching $120.90. If the rally continues, the next resistance daily resistance point comes in at its January 19 high of $121.59.

Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...